Literature DB >> 35677520

Presence of Ascites at Presentation is Associated With Absence of Long-Term Response Amongst Patients With Budd-Chiari Syndrome When Treated With Medical Therapy Alone: A Single Centre Real-Life Experience.

Dhiraj Agrawal1, Deepak Gupta1, Rohit Nathani1, Prashant Dhore1, Megha Meshram1, Shobna J Bhatia1, Akash Shukla1.   

Abstract

Background: There is lack of data on long-term outcomes of patients with Budd-Chairi Syndrome (BCS) treated with medical therapy including anticoagulation alone.
Methods: Consecutive patients (N = 138, mean [standard deviation, SD] age 29.3 [12.9] years; 66 men) with BCS, treated with medical therapy alone including anticoagulation, with minimum follow-up of 12 months were included. Initial response was classified as complete (CR), partial (PR) or nonresponse (NR) and on follow-up as loss of response (LoR) or maintenance of response (MoR). The association of baseline, clinical and biochemical parameters with different responses was evaluated.
Results: Seventy-six patients (55.1%) had CR, 26 (18.8%) had PR and 36 (26.1%) had NR. None with PR or NR had CR later. At a median follow-up of 40 (range 12-174) months, LoR was more common in PR group than in CR group (12 [46.2%] vs 18 [23.7%], P = 0.03). LoR was associated with presence of ascites (odds ratio [OR] 1.5; 95% confidence interval [CI] 0.06-0.71), gastrointestinal bleed (OR 1.33; 95% CI 0.09-0.82) or jaundice (OR 1.01; 95% CI 0.11-0.97) at baseline and duration of follow-up (OR 0.018; 95% CI 1.006-1.030). Mortality was higher in NR (28 [77.8%]) compared with CR (15 [19.7%], P = 0.001) and PR (8 [30.8%], P = 0.001). On binary logistic regression analysis, presence of ascites at baseline was associated with LoR (OR 0.303 [0.098-0.931]).
Conclusion: Patients with initial CR have better survival than nonresponders. One-third had LoR on follow-up. The presence of ascites at baseline is associated with LoR.
© 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AC-BCS, Acute on chronic BCS; BCS, Budd-Chairi Syndrome; CR, Complete response; CTP, Child-Pugh score; EVL, Endoscopic variceal band ligation; GAVE, Gastric antral vascular ectasia; GI, gastrointestinal; GOV1/2, Gastroesophageal varices 1 and 2; HVOTO, Hepatic venous outflow tract obstruction; INR, International Normalised Ratio; IVC, inferior vena cava thrombosis; LMWH, low-molecular-weight heparin; LoR, Loss of response; MELD, Model for end stage liver disease; MoR, Maintenance of response; NR, Nonresponse; PHG, portal hypertensive gastropathy; PR, Partial response; SBP, Spontaneous bacterial peritonitis; Warfarin; budd-chiari syndrome; cirrhosis; portal hypertension

Year:  2021        PMID: 35677520      PMCID: PMC9168723          DOI: 10.1016/j.jceh.2021.10.148

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  22 in total

1.  Vascular disorders of the liver.

Authors:  Laurie D DeLeve; Dominique-Charles Valla; Guadalupe Garcia-Tsao
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

2.  Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.

Authors:  Roberto de Franchis
Journal:  J Hepatol       Date:  2015-06-03       Impact factor: 25.083

Review 3.  Survival and prognostic indicators of Budd-Chiari syndrome: a systematic review of 79 studies.

Authors:  Xingshun Qi; Weirong Ren; Yongji Wang; Xiaozhong Guo; Daiming Fan
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-03-10       Impact factor: 3.869

4.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

5.  Budd-Chiari syndrome has different presentations and disease severity during adolescence.

Authors:  Akash Shukla; Pratin Bhatt; Deepak Kumar Gupta; Tejas Modi; Jatin Patel; Amit Gupte; Megha Meshram; Shobna Bhatia
Journal:  Hepatol Int       Date:  2018-07-03       Impact factor: 6.047

6.  Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study.

Authors:  Andrea De Gottardi; Thierry Thévenot; Laurent Spahr; Isabelle Morard; Solange Bresson-Hadni; Ferran Torres; Emiliano Giostra; Antoine Hadengue
Journal:  Clin Gastroenterol Hepatol       Date:  2009-05-15       Impact factor: 11.382

7.  Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome.

Authors:  Sarwa Darwish Murad; Dominique-Charles Valla; Piet C de Groen; Guy Zeitoun; Judith A M Hopmans; Elizabeth B Haagsma; Bart van Hoek; Bettina E Hansen; Frits R Rosendaal; Harry L A Janssen
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

8.  Etiology, management, and outcome of the Budd-Chiari syndrome.

Authors:  Sarwa Darwish Murad; Aurelie Plessier; Manuel Hernandez-Guerra; Federica Fabris; Chundamannil E Eapen; Matthias J Bahr; Jonel Trebicka; Isabelle Morard; Luc Lasser; Joerg Heller; Antoine Hadengue; Philippe Langlet; Helena Miranda; Massimo Primignani; Elwyn Elias; Frank W Leebeek; Frits R Rosendaal; Juan-Carlos Garcia-Pagan; Dominique C Valla; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2009-08-04       Impact factor: 25.391

9.  Prognostic indices for Budd-Chiari syndrome: valid for clinical studies but insufficient for individual management.

Authors:  Pierre-Emmanuel Rautou; Rami Moucari; Sylvie Escolano; Dominique Cazals-Hatem; Cécile Denié; Carine Chagneau-Derrode; Claire Charpignon; Victor de Lédinghen; Marieke Grenouillet-Delacre; François Habersetzer; Jean-Baptiste Nousbaum; Marie-Hélène Denninger; Dominique C Valla; Aurélie Plessier
Journal:  Am J Gastroenterol       Date:  2009-03-31       Impact factor: 10.864

10.  Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.

Authors:  Lori-Ann Linkins; Peter T Choi; James D Douketis
Journal:  Ann Intern Med       Date:  2003-12-02       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.